Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Aurigene Discovery Technologies Limited”

42 pharma patents match "Aurigene Discovery Technologies Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 42
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 42 pharmaceutical patents matching "Aurigene Discovery Technologies Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

42 results for “Aurigene Discovery Technologies Limited” · 30,257 patents in full index Clear search

  1. US 11691987

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  2. US 11542275

    Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors

    Aurigene Discovery Technologies Limited · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  3. US 11512060

    1,2,4-oxadiazole derivatives as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  4. US 11497735

    Conjoint therapies for immunomodulation

    Aurigene Discovery Technologies Limited · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  5. US 11497734

    Dual inhibitors of TIM-3 and PD-1 pathways

    Aurigene Discovery Technologies Limited · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  6. US 11465976

    1,2,4-oxadiazole and thiadiazole compounds as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  7. US 11419875

    Compounds and compositions for treating hematological disorders

    Aurigene Discovery Technologies Limited · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  8. US 11365205

    Imidazolidin-2-one compounds as PRMT5 modulators

    Aurigene Discovery Technologies Limited · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  9. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  10. US 11274123

    1,2,4-oxadiazole compounds as inhibitors of CD47 signalling

    Aurigene Discovery Technologies Limited · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  11. US 11229636

    Substituted tetrahydroquinolinone compounds as ROR gamma modulators

    Aurigene Discovery Technologies Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  12. US 11186576

    Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors

    Aurigene Discovery Technologies Limited · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  13. US 11174232

    Substituted heterocyclyl derivatives as CDK inhibitors

    Aurigene Discovery Technologies Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  14. US 11147801

    Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

    Aurigene Discovery Technologies Limited · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted
  15. US 10995100

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  16. US 10961205

    1,2,4-oxadiazole derivatives as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  17. US 10894786

    Substituted pyrazole derivatives as selective CDK12/13 inhibitors

    Aurigene Discovery Technologies Limited · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted
  18. US 10781189

    1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  19. US 10689347

    Substituted heterocyclyl derivatives as CDK inhibitors

    Aurigene Discovery Technologies Limited · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted
  20. US 10640517

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  21. US 10590093

    1,2,4-oxadiazole derivatives as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  22. US 10173989

    1,2,4-oxadiazole derivatives as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  23. US 10160736

    1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators

    Aurigene Discovery Technologies Limited · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted
  24. US 10160753

    Indazole compounds as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted